Best of 2019 - Ups and Downs with Abatacept

Save

Two recent studies have examined the effect of starting abatacept upon the risk of serious hospitalized infections or cancer, showing divergent results from claims data analyses.

Best of 2019 - War on RA - Part 3: Useless Drugs

Save

We have options that are endless – we have 28 biologics in rheumatology; 19 approved for RA in the last 20 years, but 15 of these are me-too copies or biosimilars. We currently have 2 JAK inhibitors and may have 3 or 4 by year end. But what we really need is the right drug, at the right time, in the right patient – but how will we know.

Best of 2019 - Are Non-TNF Biologics Superior to TNF inhibitors?

Save

Current ACR and EULAR guidelines list TNF-inhibitors (TNFi) abatacept, rituximab, and tocilizumab as being equally effective after methotrexate or as second line therapies when treating rheumatoid arthritis.

Best of 2019 - Methotrexate and the Risk of Lung Disease

Save

Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.

The ACR and EULAR have developed the first-ever international set of classification criteria for IgG4-RD, which was established and tested using a data-driven approach and multicriterion decision analysis – details: https://t.co/rI8dRM8kmO https://t.co/sTJ360Ouxb

#DidYouKnow Sir #WilliamOsler died ☠️ of what he called “the old man’s friend” (#pneumonia)? Learn more about the “father of #InternalMedicine” during the 💯th anniversary of his death https://t.co/0O61Qctouq. #IMProud @mcgillu @UniofOxford @JohnsHopkins @Penn @RoySocMed https://t.co/1ZS79pZrhx